Clinical Trial Update: A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase I/II study of nivolumab, ipilimumab, and plinabulin in recurrent small cell lung cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Plinabulin (plinabulin)
• Yervoy (ipilimumab)

Snippet

Sponsor: Salma Sabbour | Conditions: Lung Cancer, SCLC | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-11-12